1
项与 EGFR-IL12 CAR-T cell therapy (Pregen ShenZhen Biotechnology) 相关的临床试验Phase I/II Study of EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR -IL12 -CART) cells in metastatic patients with colorectal cancer.
100 项与 EGFR-IL12 CAR-T cell therapy (Pregen ShenZhen Biotechnology) 相关的临床结果
100 项与 EGFR-IL12 CAR-T cell therapy (Pregen ShenZhen Biotechnology) 相关的转化医学
100 项与 EGFR-IL12 CAR-T cell therapy (Pregen ShenZhen Biotechnology) 相关的专利(医药)
100 项与 EGFR-IL12 CAR-T cell therapy (Pregen ShenZhen Biotechnology) 相关的药物交易